Scott Elisofon

Dr. Elisofon serves as the Medical Director of the Liver Transplant Program. His specialties include childhood liver and biliary tract disease in addition to liver transplantation. Dr. Elisofon is board certified in Pediatric Gastroenterology and Pediatric Transplant Hepatology.

Dr. Elisofon is an active participant in SPLIT (Studies of Pediatric Liver Transplantation), a multi-center registry for Pediatric Liver Transplant. He has been a past committee member of the UNOS Pediatric Transplant Committee.

Locally, Dr. Elisofon serves on the Medical Advisory Committee for the American Liver Foundation, New England Division.

Specialties

• Biliary Atresia
• Cirrhosis in Children
• Fatty Liver Disease
• Hepatitis B
• Hepatitis C
• Hyperbilirubinemia and Jaundice
• Jaundice
• Liver Failure
• Wilson Disease

EDUCATION

Medical School

• Tufts University School of Medicine , 1999 , Boston , MA

Residency

• Children's Memorial Hospital , 2002 , Chicago , IL

Fellowship

• Pediatric Gastroenterology
• Boston Children's Hospital , 2005 , Boston , MA

Fellowship

• Hepatology
• Boston Children's Hospital , 2006 , Boston , MA

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

• Severe Acute Respiratory Syndrome Coronavirus-2 Infection in Children With Liver Transplant and Native Liver Disease: An International Observational Registry Study. J Pediatr Gastroenterol Nutr. 2021 06 01; 72(6):807-814.
• Transient elastography assessment of liver allograft fibrosis in pediatric transplant recipients. Pediatr Transplant. 2020 09; 24(6):e13736.
• Progressive multifocal leukoencephalopathy presenting with acute sensorineural hearing loss in an intestinal transplant recipient. Transpl Infect Dis. 2020 Aug; 22(4):e13304.
• The re-occurrence of cardiomyopathy in propionic acidemia after liver transplantation. JIMD Rep. 2020 Jul; 54(1):3-8.
• Biliary Atresia: Biliary-Enteric Drainage or Primary Liver Transplant? Hepatology. 2020 02; 71(2):751-752.
• Society of pediatric liver transplantation: Current registry status 2011-2018. Pediatr Transplant. 2020 02; 24(1):e13605.
• Reply to letter to the editor. J Pediatr Surg. 2020 01; 55(1):202.
• Pediatric post-transplant hepatic kaposi sarcoma due to donor-derived human herpesvirus 8. Pediatr Transplant. 2019 05; 23(3):e13384.
• Predictors of Need for Liver Transplantation in Children Undergoing Hepatoportoenterostomy for Biliary Atresia. J Pediatr Surg. 2019 Jun; 54(6):1127-1131.
• Long-term outcomes of liver transplantation for hepatoblastoma: A single-center 14-year experience. Pediatr Transplant. 2018 Jun 11; e13250.
• Bilateral native nephrectomy to reduce oxalate stores in children at the time of combined liver-kidney transplantation for primary hyperoxaluria type 1. Pediatr Nephrol. 2018 05; 33(5):881-887.
• Outcomes after discontinuation of routine use of transanastomotic biliary stents in pediatric liver transplantation at a single site. Pediatr Transplant. 2016 Aug; 20(5):647-51.
• Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 deficiency. J Allergy Clin Immunol. 2016 09; 138(3):852-859.e3.
• Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatr Blood Cancer. 2015 02; 62(2):214-218.
• Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology. 2013 Apr; 57(4):1542-9.
• Health status of patients with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2010 Dec; 51(6):759-65.
• Hepatic failure in a rapidly involuting congenital hemangioma of the liver: failure of embolotherapy. Pediatr Radiol. 2009 Oct; 39(10):1118-23.
• Hepatitis B and C in children: current treatment and future strategies. Clin Liver Dis. 2006 Feb; 10(1):133-48, vii.